Next Generation SERDs Progress In Breast Cancer; Standing Out In The Crowd Won't Be Easy

 
• By Jessica Merrill

The class is poised to be a competitive one with Sanofi, AstraZeneca, Roche and Zentalis among the contenders developing new selective estrogen receptor degraders for HER2-negative breast cancer.

How to stand out - sales, marketing & advertising! Business concept - branding, different, original.
Several drug makers are looking to stand out in the SERD class • Source: Shutterstock

More from ASCO

More from Conferences